Thiola

The dosage of Tiopronin must be highly individualized based on the patient's urinary cystine excretion and stone-forming tendency. The clinical goal is to maintain urinary cystine concentrations below 250 mg/L. For most adults, the initial recommended dose is approximately 800 mg per day. Depending on the clinical response and follow-up lab results, the maintenance dose typically ranges from 400 mg to 1,000 mg per day, divided into three separate doses. In cases of severe cystinuria where stone formation persists, some healthcare providers may increase the total daily dose up to 2,000 mg, provided the patient tolerates the medication without significant adverse effects. Your doctor will likely perform a 24-hour urine collection approximately one month after starting therapy to determine if the dose needs adjustment.

Tiopronin is approved for use in pediatric patients. The dosage is generally calculated based on body weight. The typical starting dose for children is approximately 15 mg/kg/day, divided into three doses given at equal intervals. As with adults, the dose is titrated based on the 24-hour urinary cystine excretion levels. Pediatric patients require close monitoring of growth and development, as well as regular screening for proteinuria, which can be a serious side effect in this population. If a child is unable to swallow tablets, healthcare providers should be consulted for alternative administration strategies, though crushing tablets may affect the pharmacokinetic profile of delayed-release versions.

Renal Impairment

There are no specific quantitative guidelines for Tiopronin dosage in patients with pre-existing renal impairment. However, since the drug and its metabolites are primarily excreted by the kidneys, and because Tiopronin itself can cause nephrotoxicity (proteinuria), extreme caution is advised. Healthcare providers will monitor creatinine clearance and urinary protein levels more frequently in these individuals.

Hepatic Impairment

Tiopronin has been associated with rare cases of hepatotoxicity. Patients with significant liver disease should be monitored closely for changes in liver function tests (LFTs). Dose reductions may be considered if liver enzymes become elevated during therapy.

Elderly Patients

Clinical studies of Tiopronin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.

For optimal efficacy, Tiopronin should be taken on an empty stomach, either one hour before or two hours after a meal. This timing helps ensure consistent absorption. It is critical to maintain high fluid intake while taking this medication; patients are often advised to drink at least 3 liters of fluid per day (and at least two glasses of water with each dose and at bedtime) to help dilute the urine. Tablets should be swallowed whole; do not crush or chew delayed-release tablets as this can lead to rapid drug release and increased side effects. Store the medication at room temperature, away from moisture and direct sunlight.

If you miss a dose of Tiopronin, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed one. Consistency is key to maintaining low urinary cystine levels throughout a 24-hour period.

Information regarding Tiopronin overdose is limited. Symptoms of an acute overdose may include severe nausea, vomiting, abdominal pain, and an increased risk of hypersensitivity reactions. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is generally supportive, focusing on maintaining hydration and monitoring renal and hepatic function.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to a rapid recurrence of kidney stones.

Tiopronin is associated with a high incidence of adverse reactions, many of which are similar to those seen with penicillamine (another thiol drug). The most common side effects include gastrointestinal distress, such as nausea, vomiting, diarrhea, and abdominal pain. These symptoms often occur early in treatment and may diminish as the body adjusts to the medication. Another very common side effect is a change in taste (dysgeusia) or a complete loss of taste (ageusia), which can impact appetite. Dermatologic reactions, including various types of skin rashes (morbilliform or urticarial), are also frequently reported. These rashes may be accompanied by itching (pruritus). In some cases, patients may experience a 'sulfur' odor to their breath or skin due to the thiol group in the medication.

Between 1% and 10% of patients may experience more significant systemic reactions. These include fever, joint pain (arthralgia), and muscle pain (myalgia). Some patients report fatigue, weakness, or a general feeling of being unwell (malaise). Oral ulcers or sores in the mouth (stomatitis) can occur, making eating uncomfortable. There may also be mild elevations in liver enzymes or minor changes in blood counts, such as a slight decrease in white blood cells (leukopenia). Swelling of the lymph nodes (lymphadenopathy) has also been noted in this frequency range.

Rare but serious side effects include severe hematologic abnormalities such as aplastic anemia, agranulocytosis (a dangerous drop in white blood cells), and thrombocytopenia (low platelet count). Neurological side effects like peripheral neuropathy (numbness or tingling in the hands and feet) or myasthenia-like symptoms (muscle weakness) are rare but require immediate attention. Some patients may develop a lupus-like syndrome, characterized by a butterfly rash on the face, joint pain, and positive ANA (antinuclear antibody) tests. Skin conditions like pemphigus (blistering) or elastosis perforans serpiginosa (a connective tissue disorder) have been documented in rare instances.

> Warning: Stop taking Tiopronin and call your doctor immediately if you experience any of these symptoms. These may indicate a life-threatening reaction or organ damage.

• Proteinuria/Nephrotic Syndrome: This is the most significant serious risk. If you notice foamy urine, swelling in your ankles or feet (edema), or rapid weight gain, it may indicate that Tiopronin is damaging the filters in your kidneys. This can progress to nephrotic syndrome, a serious kidney condition.
• Severe Allergic Reactions: Signs include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat (anaphylaxis).
• Blood Dyscrasias: Unexplained bruising, tiny red spots on the skin (petechiae), sore throat, fever, or extreme paleness may indicate a severe drop in blood cells.
• Hepatotoxicity: Yellowing of the eyes or skin (jaundice), dark urine, or severe right-sided abdominal pain.
• Goodpasture Syndrome: Though extremely rare, this involves lung hemorrhage and kidney failure. Seek help for shortness of breath or coughing up blood.

With prolonged use, Tiopronin can affect connective tissue. Some patients develop skin thinning, increased bruising, or impaired wound healing. The risk of developing chronic proteinuria increases with the duration of therapy, necessitating lifelong monitoring of kidney function. There is also a theoretical risk of affecting collagen cross-linking, which may impact skin elasticity over many years. Regular dermatologic and renal evaluations are essential for patients on long-term Tiopronin therapy.

At this time, Tiopronin does not carry an FDA Black Box Warning. However, the potential for severe, life-threatening reactions—particularly renal and hematologic toxicities—is well-documented in the 'Warnings and Precautions' section of the official prescribing information. The lack of a black box does not imply that the drug is without significant risk; rather, it emphasizes the need for vigilant clinical monitoring.

Report any unusual symptoms to your healthcare provider promptly to ensure safe management of your condition.

Tiopronin is a potent medication that requires careful medical supervision. It is not a simple supplement but a reactive chemical agent that can affect multiple organ systems. The most critical safety aspect of Tiopronin therapy is the high frequency of adverse reactions, which may occur in up to 50% of patients. Many of these reactions are immunologically mediated. Patients must be committed to regular laboratory monitoring and must be able to recognize early signs of toxicity. It is also vital to maintain extreme hydration (3+ liters of fluid daily) to assist the medication's goal of preventing stone formation.

No FDA black box warnings for Tiopronin. However, the FDA-approved labeling contains extensive warnings regarding the risk of proteinuria, nephrotic syndrome, and hematologic toxicity, which can be fatal if not managed appropriately.

• Allergic Reactions / Anaphylaxis Risk: Patients who have had a severe reaction to penicillamine are at a significantly higher risk of reacting to Tiopronin. Cross-sensitivity is common. Anaphylactic shock has been reported; therefore, the first few doses should be monitored closely.
• Nephrotoxicity: Tiopronin can cause significant kidney damage, most commonly manifesting as proteinuria (excess protein in the urine). In some cases, this can lead to nephrotic syndrome. Treatment must be discontinued if proteinuria becomes severe.
• Hematologic Toxicity: The drug can suppress bone marrow function, leading to dangerously low levels of white blood cells, red blood cells, or platelets. This increases the risk of infection, anemia, and bleeding.
• Hepatotoxicity: While less common than renal issues, liver injury can occur. Baseline and periodic liver function tests are recommended.
• Pulmonary Complications: Rare instances of pulmonary infiltrates or hemoptysis (coughing up blood) have been reported. Any new respiratory symptoms should be evaluated immediately.

Because of the high risk of toxicity, a strict monitoring schedule is required:

1. 1Urinalysis: Before starting therapy and every 3–6 months thereafter, a 24-hour urine collection is needed to measure cystine levels and check for protein. Qualitative 'dipstick' tests for protein should be performed more frequently (e.g., monthly).
2. 2Complete Blood Count (CBC): Regular blood tests are necessary to monitor for leukopenia, thrombocytopenia, and anemia.
3. 3Liver Function Tests (LFTs): Periodic monitoring of ALT, AST, and bilirubin levels.
4. 4Physical Exams: Regular checks for skin rashes, lymphadenopathy, and edema.

Tiopronin is generally not known to cause significant sedation or cognitive impairment. However, if you experience rare side effects like muscle weakness or severe fatigue, you should avoid driving or operating heavy machinery until you know how the medication affects you.

Patients taking the delayed-release formulation (Thiola EC) must strictly avoid alcohol. Alcohol can cause 'dose-dumping,' where the entire dose of the medication is released into the bloodstream at once instead of slowly over time. This can lead to toxic plasma levels and severe side effects. For immediate-release forms, alcohol should still be limited as it can contribute to dehydration, which worsens cystinuria.

Tiopronin does not typically cause a withdrawal syndrome. However, stopping the medication abruptly will lead to a rapid increase in urinary cystine levels, significantly increasing the risk of new stone formation within days. If the drug must be stopped due to toxicity, your doctor will implement alternative strategies (like aggressive fluid and alkali therapy) to protect your kidneys.

> Important: Discuss all your medical conditions, especially any history of kidney or blood disorders, with your healthcare provider before starting Tiopronin.

While there are few absolute contraindications for drug combinations, Tiopronin should generally not be used with other medications known to cause similar severe toxicities, such as gold salts (used for rheumatoid arthritis) or antimalarial agents like chloroquine, as these can synergistically increase the risk of bone marrow suppression and kidney damage. Using Tiopronin with other thiol-containing drugs (like penicillamine) is generally avoided because if a patient cannot tolerate one, they are unlikely to tolerate the other, and the combined toxicity profile is unacceptably high.

• Immunosuppressants: Medications like azathioprine, methotrexate, or cyclophosphamide, when used with Tiopronin, significantly increase the risk of severe hematologic toxicity (leukopenia and thrombocytopenia). If these must be used together, blood counts must be monitored weekly.
• Nephrotoxic Agents: Drugs that can damage the kidneys, such as NSAIDs (ibuprofen, naproxen) or certain antibiotics (aminoglycosides), should be used with extreme caution. The combined effect on the renal tubules can accelerate the development of proteinuria.

• Antihypertensives: Some blood pressure medications, particularly ACE inhibitors (like lisinopril), can also cause proteinuria or affect renal function. When combined with Tiopronin, the risk of kidney-related side effects may be additive.
• Zinc and Copper Supplements: Tiopronin is a chelating agent. It may bind to essential trace metals in the gut or blood, potentially leading to deficiencies in zinc or copper over long periods. Your doctor may recommend periodic testing of these mineral levels.

• High-Protein Diet: Cystine is derived from methionine, an amino acid found in protein. A high-protein diet increases the amount of cystine the kidneys must excrete, potentially overwhelming the effects of Tiopronin. Patients are usually advised to follow a moderate-to-low protein diet.
• Sodium Intake: High sodium intake increases urinary cystine excretion. Patients should maintain a low-sodium diet to maximize the efficacy of Tiopronin.
• Timing: Taking Tiopronin with food can reduce its absorption. It is best taken on an empty stomach (1 hour before or 2 hours after meals).

There is limited data on Tiopronin interactions with herbal products. However, supplements that affect kidney function or have mild diuretic effects (like dandelion root or parsley) should be discussed with a doctor. Supplements with antioxidant properties (like N-acetylcysteine) also contain thiol groups and might theoretically interfere with or add to the effects of Tiopronin in unpredictable ways.

Tiopronin can interfere with certain laboratory tests that rely on colorimetric reactions. Specifically, it may cause a false-positive result in urinary ketone tests that use nitroprusside (like Ketostix). It may also affect the results of certain tests for uric acid or glucose. Always inform laboratory personnel that you are taking Tiopronin.

For each major interaction, the mechanism usually involves either additive toxicity (pharmacodynamic) or interference with the chemical assay (in the case of lab tests). Management typically involves dose adjustment, increased monitoring frequency, or choosing alternative medications.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to prevent dangerous interactions.

• Hypersensitivity to Tiopronin: Any patient with a documented history of severe allergic reactions (anaphylaxis, Stevens-Johnson Syndrome, or toxic epidermal necrolysis) to Tiopronin must never take the drug again. The risk of a fatal re-exposure is high.
• History of Severe Hematologic Disorders: Patients who have previously developed agranulocytosis, aplastic anemia, or severe thrombocytopenia while taking thiol-containing drugs (like penicillamine or Tiopronin) should not be prescribed this medication. The bone marrow suppression can be irreversible upon re-exposure.
• Severe Renal Insufficiency/Nephrotic Syndrome: If a patient already has significant pre-existing protein loss in the urine or advanced kidney failure, Tiopronin is contraindicated because it can exacerbate these conditions rapidly.
• Breastfeeding: Due to the potential for serious adverse reactions in the nursing infant, Tiopronin is contraindicated in women who are breastfeeding.

• Mild-to-Moderate Renal Impairment: Requires a careful risk-benefit analysis. The drug may still be used if the risk of stone-induced kidney loss is greater than the risk of drug-induced nephrotoxicity, but monitoring must be intensified.
• Liver Disease: Patients with active hepatitis or cirrhosis require close monitoring of LFTs, as the drug is metabolized in the liver and has been linked to rare hepatotoxicity.
• Autoimmune Disorders: Patients with systemic lupus erythematosus (SLE) or myasthenia gravis may experience a worsening of their condition, as Tiopronin can induce autoimmune-like syndromes.

There is a high rate of cross-sensitivity between Tiopronin and penicillamine. Approximately 30% to 50% of patients who experience a side effect on penicillamine will also experience a side effect on Tiopronin. However, many patients who cannot tolerate penicillamine can tolerate Tiopronin, making it a valuable second-line option. If the previous reaction to penicillamine was life-threatening (e.g., aplastic anemia), Tiopronin should be avoided entirely.

> Important: Your healthcare provider will evaluate your complete medical history, including previous drug allergies and kidney function, before prescribing Tiopronin.

Tiopronin is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown some evidence of fetal harm at high doses. However, untreated cystinuria during pregnancy poses significant risks, including painful stone episodes, urinary tract infections, and potential kidney damage to the mother. Therefore, Tiopronin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. If used, the lowest effective dose should be employed, and the patient should be monitored closely for proteinuria, which can be complicated by the physiological changes of pregnancy.

It is not known whether Tiopronin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Tiopronin (including effects on collagen and blood cells), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Most clinical guidelines recommend against breastfeeding while taking this medication.

Tiopronin is approved for use in children with homozygous cystinuria. Dosing is weight-based (typically 15 mg/kg/day). The safety profile in children is similar to that in adults, with a particular emphasis on monitoring for proteinuria and hematologic changes. Long-term effects on growth and bone development have not been extensively studied, so pediatricians should monitor these parameters closely during chronic therapy.

Clinical experience has not identified significant differences in responses between the elderly and younger patients. However, since elderly patients are more likely to have decreased renal function, the risk of toxic reactions to this drug may be greater. Dose selection should be cautious, starting at the lower end of the range, and renal function (creatinine clearance) should be assessed before and during therapy.

In patients with pre-existing renal impairment, the clearance of Tiopronin may be reduced, leading to higher plasma levels and an increased risk of toxicity. There are no specific GFR-based dosing tables, but clinicians typically use a 'start low, go slow' approach. If the GFR is significantly reduced, the drug may be ineffective because it cannot reach the urine in sufficient concentrations to complex with cystine.

Patients with hepatic impairment should be monitored for signs of increased drug toxicity. While the liver is not the primary route of excretion, it is involved in the metabolism of the drug. If jaundice or significant elevations in LFTs occur, the drug should be discontinued immediately.

> Important: Special populations require individualized medical assessment and more frequent laboratory monitoring to ensure safety.

Tiopronin [N-(2-Mercaptopropionyl)glycine] is an active reducing agent that operates via a thiol-disulfide exchange reaction. Its primary target is the disulfide bond of cystine. In the urine, Tiopronin's free sulfhydryl group (-SH) attacks the disulfide bridge of the relatively insoluble cystine molecule. This results in the formation of a mixed disulfide (tiopronin-cysteine) and a free cysteine molecule. The mixed disulfide is significantly more soluble (up to 50 times more) than pure cystine at a physiological urinary pH. By shifting the equilibrium away from solid cystine crystals toward soluble disulfides, the drug prevents the nucleation and growth of kidney stones.

The pharmacodynamic effect of Tiopronin is directly related to its concentration in the urine. The onset of action is rapid, with a reduction in urinary cystine levels typically observed within 24 to 48 hours of the first dose. The duration of effect is short, lasting only as long as the drug is being excreted; once the medication is stopped, urinary cystine levels return to baseline within approximately 2-3 days. There is no evidence of the development of pharmacological tolerance, although the underlying severity of cystinuria may change over time, requiring dose adjustments.

| Parameter | Value |

|---|---|

| Bioavailability | 85-90% (Immediate Release) |

| Protein Binding | ~50% (primarily to Albumin) |

| Half-life | 3.7 - 6.2 hours |

| Tmax | 1 - 2 hours |

| Metabolism | Liver/Plasma (Thiol-disulfide exchange) |

| Excretion | Renal (78% within 24 hours) |

• Molecular Formula: C5H9NO3S
• Molecular Weight: 163.2 g/mol
• Solubility: Soluble in water and alcohol.
• Structure: A synthetic thiol compound consisting of a glycine moiety acylated with 2-mercaptopropionic acid.

Tiopronin belongs to the 'Reducing and Complexing Thiol' class. It is therapeutically categorized as a urinary tract product and an antilithic (stone-preventing) agent. It is chemically related to other thiol drugs like penicillamine and captopril, though it is generally more potent than penicillamine on a milligram-for-milligram basis in reducing cystine excretion.